ArticleTranslational cancer research2026
Magnetic resonance imaging-based radiomics analysis: predicting vascular invasion in breast invasive ductal carcinoma using different machine learning models.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphovascular invasion (LVI) is an adverse prognostic factor; preoperative prediction by imaging is difficult, but radiomics extracts quantitative tumor biology features. Investigating the value of combining magnetic resonance imaging (MRI)-based radiomics features with multiple machine learning (ML) models in predicting LVI status in invasive ductal carcinoma (IDC) of the breast. Methods: A retrospective cohort of 678 female patients with pathologically confirmed IDC of the breast was collected from June 2021 to June 2025. All patients underwent preoperative MRI. Based on postoperative pathology, patients were categorized into LVI-positive (n=258) and LVI-negative (n=420) groups. Using ITK-SNAP software, regions of interest (ROIs) were delineated in phase-3 dynamic contrast-enhanced MRI images to extract radiomics features. Feature selection and dimensionality reduction were performed using redundancy analysis and the least absolute shrinkage and selection operator (LASSO) regression. Data were randomly split into an 8:2 ratio for training (n=542) and testing (n=136) sets. Eight ML models were then constructed: logistic regression (LR), support vector machine (SVM), K-nearest neighbors (KNN), random forest, extreme random trees (ExtraTrees), extreme gradient boosting (XGBoost), light gradient boosting machine (LightGBM), and multi-layer perceptron (MLP). Univariate and multivariate LR analyses were performed to screen clinical and radiological features for establishing clinical models. Concurrently, a combined model integrating radiomics features with clinical characteristics was developed. The discriminatory power of each model was evaluated using the area under the curve (AUC). AUC values for the radiological model, clinical model, and combined model underwent statistical comparison via Delong's test. Decision curve analysis (DCA) was employed to assess their clinical utility. Results: A total of 1,197 radiomics features were extracted, and after dimensionality reduction, 23 features with the highest predictive value were selected. The clinical prediction model constructed based on multifactorial analysis results indicated that LVI positivity was more likely to occur in postmenopausal patients [odds ratio (OR) =1.690; 95% confidence interval (CI): 1.174-2.433], those with higher histological grade (OR =1.527; 95% CI: 1.107-2.107), sentinel lymph node metastasis (OR =0.198; 95% CI: 0.137-0.285), distinct molecular subtypes (OR =0.740; 95% CI: 0.567-0.965), and MRI maximum diameter ≥2 cm (OR =2.059; 95% CI: 1.362-3.113). Among radiomics models, the XGBoost model demonstrated optimal performance with a training set AUC of 0.912 and a validation set AUC of 0.706. The combined model exhibited the highest discriminatory ability in the training set (AUC =0.956) and a validation set AUC of 0.778. DCA indicated the combined model provided higher clinical net benefit. Conclusions: A combined model incorporating MRI radiomics features and clinical factors demonstrates predictive value for the presence or absence of LVI in IDC of the breast, serving as a reference for individualized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.